[go: up one dir, main page]

WO2002002743A3 - The nip3 family of proteins - Google Patents

The nip3 family of proteins Download PDF

Info

Publication number
WO2002002743A3
WO2002002743A3 PCT/US2001/021043 US0121043W WO0202743A3 WO 2002002743 A3 WO2002002743 A3 WO 2002002743A3 US 0121043 W US0121043 W US 0121043W WO 0202743 A3 WO0202743 A3 WO 0202743A3
Authority
WO
WIPO (PCT)
Prior art keywords
bnip3
necrosis
protein
nip
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021043
Other languages
French (fr)
Other versions
WO2002002743A2 (en
Inventor
Kenneth I Kohn
Arnold H Di Greenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
University of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba filed Critical University of Manitoba
Priority to CA002413250A priority Critical patent/CA2413250A1/en
Priority to AU2001271767A priority patent/AU2001271767A1/en
Priority to EP01950808A priority patent/EP1299127A2/en
Publication of WO2002002743A2 publication Critical patent/WO2002002743A2/en
Publication of WO2002002743A3 publication Critical patent/WO2002002743A3/en
Priority to US10/290,461 priority patent/US7452869B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

There is provided an isolated and purified BNIP3 protein. There is also provided a method for inducing necrosis in cells by transfecting a cell with a BNIP3 protein. A method for inducing necrosis in cells by creating a transgene overexpressing the gene for the BNIP3 protein is also provided. A transgenic animal and progeny thereof is provided having an expression factor consisting essentially of a BNIP3 protein selected from the group consisting essentially of Seq. ID 1 and 2. Also provided is a vector for use in treating disease including BNIP3 or DN NIP and a promoter. A gene therapy having DNA encoding BNIP3 or DN NIP and a promoter, whereby said gene therapy is used to induce necrosis or inhibit necrosis is also provided.
PCT/US2001/021043 2000-06-30 2001-06-29 The nip3 family of proteins Ceased WO2002002743A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002413250A CA2413250A1 (en) 2000-06-30 2001-06-29 The nip3 family of proteins
AU2001271767A AU2001271767A1 (en) 2000-06-30 2001-06-29 The nip3 family of proteins
EP01950808A EP1299127A2 (en) 2000-06-30 2001-06-29 The nip3 family of proteins
US10/290,461 US7452869B2 (en) 2000-06-30 2002-11-08 NIP3 family of proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21564300P 2000-06-30 2000-06-30
US60/215,643 2000-06-30
US21955400P 2000-07-20 2000-07-20
US60/219,554 2000-07-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/290,461 Continuation-In-Part US7452869B2 (en) 2000-06-30 2002-11-08 NIP3 family of proteins

Publications (2)

Publication Number Publication Date
WO2002002743A2 WO2002002743A2 (en) 2002-01-10
WO2002002743A3 true WO2002002743A3 (en) 2002-05-16

Family

ID=26910247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021043 Ceased WO2002002743A2 (en) 2000-06-30 2001-06-29 The nip3 family of proteins

Country Status (4)

Country Link
EP (1) EP1299127A2 (en)
AU (1) AU2001271767A1 (en)
CA (1) CA2413250A1 (en)
WO (1) WO2002002743A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256636A1 (en) * 2002-07-22 2004-02-09 University Of Miami Preventing ischemia-induced cell damage
WO2023079141A2 (en) 2021-11-05 2023-05-11 Tienush Rassaf Amelioration and treatment of infarction damage

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TSUNODA ET AL.: "Effects of wild-type and mutated p53 and Id proteins on the induction of apoptosis by adenovirus E1A, c-Myc, Bax and Nip3 in p53 null mouse cerebellum cells", BIOCHEM. BIOPHYS. RES. COMM., vol. 255, 1999, pages 722 - 730, XP002908157 *
VANDE VELDE ET AL.: "BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore", MOLECULAR AND CELLULAR BIOLOGY, vol. 20, no. 15, August 2000 (2000-08-01), pages 5454 - 5468, XP002908158 *

Also Published As

Publication number Publication date
CA2413250A1 (en) 2002-01-10
WO2002002743A2 (en) 2002-01-10
EP1299127A2 (en) 2003-04-09
AU2001271767A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
Gudmundsson et al. Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL-39.
US6448391B1 (en) Ubiquitin-lytic peptide gene promoter
DE59209981D1 (en) RECOMBINANT CORE STREPTAVIDINE
WO2001072976A3 (en) 32142, 21481, 25964, 21686, novel human dehydrogenase molecules and uses therefor
WO2000073478A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
IL87041A0 (en) Induction of virus resistance in plants,recombinant dna molecules for use therein,their preparation and vectors and host cells comprising them
WO2001090323A3 (en) 46638, a putative family member of human lipoxygenase
WO2001038357A3 (en) Jaffa, a novel fibroblast growth factor family member and uses therefor
US20080009447A1 (en) Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of SOCS sequence in the animal
WO2002002743A3 (en) The nip3 family of proteins
ATE312184T1 (en) PROMOTER FOR REGULATION OF FOREIGN GENE EXPRESSION
WO2002002760A3 (en) 25869, a human carboxylesterase and uses thereof
WO2003048325A3 (en) Nucleotide sequences of shrimp beta-actin and actin promoters and their use in genetic transformation technology
CA2404471A1 (en) A construct capable of release in closed circular form from a larger nucleotide sequence permitting site specific expression and/or developmentally regulated expression of selected genetic sequences
WO1999027093A3 (en) The nip3 family of proteins
CA2310726A1 (en) Plant seedling and embryo promoter
WO2002006485A3 (en) 47885, a novel human ubiquitin-activating enzyme and uses therefor
WO2002044357A3 (en) Methods of using 18903 to treat pain and pain-related disorders
WO2002000863A3 (en) 32140, a novel human aldehyde dehydrogenase and uses therefor
WO2002016588A3 (en) 15985, a human serine/threonine protein kinase family membe r and uses thereof
WO2001090145A3 (en) 57805, a human cadherin family member and uses thereof
WO2002040674A3 (en) '67118', '67067' and '62092', human proteins and methods of use thereof
WO2002024911A3 (en) 63760, a novel human transporter and uses thereof
WO2001081559A3 (en) 26335, a novel human serine/threonine dehydratase and uses thereof
WO2002029037A3 (en) 57800, a novel human cadherin and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10290461

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2413250

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001950808

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001950808

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWW Wipo information: withdrawn in national office

Ref document number: 2001950808

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP